Literature DB >> 19837059

Immunotherapy of cancer.

Hossein Borghaei1, Mitchell R Smith, Kerry S Campbell.   

Abstract

Major advances have been made in the field of immunology in the past two decades. A better understanding of the molecular and cellular mechanisms controlling the immune system has opened the door to many innovative and promising new cancer therapies that manipulate the immune response. For instance, toll-like receptor agonists have been shown to boost immune responses toward tumors. Also, a wide array of cell-based immunotherapies utilizing T cells, NK cells, and dendritic cells have been established. Furthermore, a rapidly expanding repertoire of monoclonal antibodies is being developed to treat tumors, and many of the available antibodies have demonstrated impressive clinical responses. Here, we examine some of these immunotherapeutic approaches currently in use or testing to treat cancer, and we examine available evidence with regards to mechanism and efficacy of these treatments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837059      PMCID: PMC2783916          DOI: 10.1016/j.ejphar.2009.09.067

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  185 in total

1.  Functional analysis of TRAIL receptors using monoclonal antibodies.

Authors:  T S Griffith; C T Rauch; P J Smolak; J Y Waugh; N Boiani; D H Lynch; C A Smith; R G Goodwin; M Z Kubin
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 3.  Use of natural killer cells in hematopoetic stem cell transplantation.

Authors:  J R Passweg; M Stern; U Koehl; L Uharek; A Tichelli
Journal:  Bone Marrow Transplant       Date:  2005-04       Impact factor: 5.483

4.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

5.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

6.  Human diversity in killer cell inhibitory receptor genes.

Authors:  M Uhrberg; N M Valiante; B P Shum; H G Shilling; K Lienert-Weidenbach; B Corliss; D Tyan; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

7.  Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Authors:  John P Leonard; Morton Coleman; Jamie C Ketas; Amy Chadburn; Richard Furman; Michael W Schuster; Eric J Feldman; Michelle Ashe; Stephen J Schuster; William A Wegener; Hans J Hansen; Heather Ziccardi; Michael Eschenberg; Urte Gayko; Scott Z Fields; Alessandra Cesano; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival.

Authors:  Diana Starlets; Yael Gore; Inbal Binsky; Michal Haran; Nurit Harpaz; Lev Shvidel; Shirly Becker-Herman; Alain Berrebi; Idit Shachar
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 10.  Vaccines against cervical cancer.

Authors:  Linda J Rogers; Lois J Eva; David Michael Luesley
Journal:  Curr Opin Oncol       Date:  2008-09       Impact factor: 3.645

View more
  29 in total

1.  Anti-tumour effects of polysaccharides isolated from Artemisia annua L by inducing cell apoptosis and immunomodulatory anti-hepatoma effects of polysaccharides.

Authors:  Jiayu Chen; Jiaqi Chen; Xintai Wang; Chibo Liu
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-11-02

2.  Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays.

Authors:  Mariana M Mata; Fareeha Mahmood; Ryan T Sowell; Linda L Baum
Journal:  J Immunol Methods       Date:  2014-02-20       Impact factor: 2.303

3.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

Review 4.  Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.

Authors:  Kanchan Sonkar; Vinay Ayyappan; Caitlin M Tressler; Oluwatobi Adelaja; Ruoqing Cai; Menglin Cheng; Kristine Glunde
Journal:  NMR Biomed       Date:  2019-06-11       Impact factor: 4.044

5.  A new avenue to cure cancer by turning adaptive immune T cells to innate immune NK cells via reprogramming.

Authors:  Dong-Ming Su; Ramakrishna Vankayalapati
Journal:  J Mol Cell Biol       Date:  2010-08-05       Impact factor: 6.216

6.  Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells.

Authors:  Suresh Chava; Suresh Bugide; Romi Gupta; Narendra Wajapeyee
Journal:  J Vis Exp       Date:  2020-02-22       Impact factor: 1.355

Review 7.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

8.  Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries.

Authors:  Ivan Marques Borrello; Madeline Mag Schaffer; Elena Roehrl; Jessica Falco Marshall
Journal:  Mol Clin Oncol       Date:  2014-01-14

Review 9.  Materials from peptide assembly: towards the treatment of cancer and transmittable disease.

Authors:  Monica C Branco; Dina M Sigano; Joel P Schneider
Journal:  Curr Opin Chem Biol       Date:  2011-04-18       Impact factor: 8.822

10.  Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice.

Authors:  Francesca Kalli; Rodolfo Machiorlatti; Florinda Battaglia; Alessia Parodi; Giuseppina Conteduca; Francesca Ferrera; Michele Proietti; Samuele Tardito; Marina Sanguineti; Enrico Millo; Daniela Fenoglio; Raffaele De Palma; Giorgio Inghirami; Gilberto Filaci
Journal:  J Transl Med       Date:  2013-05-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.